Landscape Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Landscape Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,487	Closed	-$131K	–	836
2026 Q1	$131K	Sell	15,487 -6	-0%	-$57	0.01%	664
2025 Q4	$188K	Buy	+15,493	New	+$188K	0.01%	618
2024 Q2	–	Sell	-23,039	Closed	-$210K	–	848
2024 Q1	$210K	Buy	+23,039	New	+$164K	0.02%	605
2017 Q4	–	Sell	-11,289	Closed	-$70K	–	721
2017 Q3	$70K	Buy	+11,289	New	+$72.7K	0.01%	486
2016 Q1	–	Sell	-35,665	Closed	-$334K	–	747
2015 Q4	$334K	Buy	+35,665	New	+$385K	0.04%	654

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Landscape Capital Management's OCUL Position: Q2 2026 in Review

Landscape Capital Management sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 15,487 shares — an estimated $131K sold.

Landscape Capital Management first reported a position in OCUL in Q4 2015 and held it in 5 quarters. The position peaked at $334K in Q4 2015. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Landscape Capital Management reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
Landscape Capital Management sold 15,487 Ocular Therapeutix shares in Q2 2026, an estimated $131K.
Landscape Capital Management first reported a position in Ocular Therapeutix in Q4 2015 and held it in 5 quarters.
Landscape Capital Management's Ocular Therapeutix position peaked at $334K in Q4 2015.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Landscape Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.